Expand GelrinC

Regentis Biomaterials Secures Japanese Patent to Expand GelrinC Manufacturing and IP Portfolio in Global Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT) has obtained a Japanese patent allowance that strengthens its intellectual property protection for the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, its cell-free hydrogel for knee cartilage repair. This milestone follows a re…